This study is looking at whether using the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) can help people with type 2 diabetes stay on their GLP-1 or GLP-1/GIP combination medications for a longer time. These medications, like GLP-1 and GIP/GLP-1 agonists, are used to manage diabetes. You might be able to join if you are at least 18 years old, have type 2 diabetes, and are about to start taking one of these medications. The study aims to see how long people in each group stay on their medication, measured over 210 days. The current recruitment status is unclear.

Study design

This is an observational study with up to 800 participants across the United States. Participants will be randomly assigned to either use the FreeStyle Libre 3 system or their usual diabetes care.

What's involved

You would be on the study for approximately 210 days. You would wear a sensor on your upper arm and use a paired smartphone to collect glucose readings.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for approximately 210 days to assess how long they remain on their GLP-1 or GLP-1/GIP medication.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.